|
|
monomeric annexin A2 |
|
Vaxjo ID |
310 |
|
Vaccine Adjuvant Name |
monomeric annexin A2 |
|
Alternative Names |
ANXA2m |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
Monomeric annexin A2 (ANXA2m) is an oxygen-regulated Toll-like receptor 2 (TLR2) ligand and adjuvant. It is a pleiotropic, calcium-dependent, phospholipid-binding protein. It can exist as a monomer or heterotetramer, and be intracellular, membrane-bound, or secreted. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein with a broad tissue distribution |
|
Structure |
The paper discusses monomeric ANXA2 and mentions that the amino-terminal 15 amino acids are necessary and sufficient for TLR2 binding and DC activation. |
|
Preparation |
Purified ANXA2m and ANXA2-derived peptides were used in experiments. |
|
Function |
ANXA2m is overexpressed by murine glioblastoma GL261 cells grown under 5 % O2, but not atmospheric 20 % O2, and acts as an adjuvant by inducing murine and human DC maturation through TLR2. ANXA2m upregulates CD80 and CD86 expression, enhances antigen cross-presentation, and induces the secretion of IL-12p70, TNF-α, and IFN-α. |
| Related Vaccine(s) |
|
| References |
Andersen et al., 2016: Andersen BM, Xia J, Epstein AL, Ohlfest JR, Chen W, Blazar BR, Pennell CA, Olin MR. Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant. Journal for immunotherapy of cancer. 2016; 4; 11. [PubMed: 26885373].
|
|
